http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105727285-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-079 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105727285-B |
| titleOfInvention | A kind of application of monoclonal antibody in neurodegenerative disease is treated |
| abstract | The invention discloses a kind of application of monoclonal antibody in neurodegenerative disease is treated.Specifically, the present invention provides a kind of purposes of monoclonal antibody, are used to prepare the pharmaceutical composition for the treatment of neurodegenerative disease；Wherein, the sequence of the monoclonal antibody is as shown in SEQ ID NO.1.It is demonstrated experimentally that monoclonal antibody of the present invention and preparation have significant therapeutic effect to neurodegenerative disease, and the effect has significant dose dependent. |
| priorityDate | 2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 150.